Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Jul 28;8(3):E493–E500. doi: 10.1208/aapsj080358

Rapid in vivo oral screening in rats: Reliability, acceptance criteria, and filtering efficiency

Hong Mei 1,✉, Walter Korfmacher 1, Richard Morrison 1
PMCID: PMC2761056  PMID: 17025267

Abstract

The reliability and acceptance criteria of rapid oral exposure screening were evaluated by pharmacokinetic simulations and by comparing oral exposure of 100 proprietary compounds from 15 therapeutic programs obtained at different times by cassette accelerated rapid rat screen (CARRS) and conventional pharmacokinetic (full-PK) procedures. Once acceptance criteria were established, the filtering efficiency (discard rate) was assessed with a larger data set of 5289 compounds tested by CARRS only. These evaluations indicated that area under the concentration-time curve during the first 6 hours (AUC6h) capture>50% of AUC∞ for most (71%) of the compounds and AUC6h from CARRS is comparable to AUC6h from full-PK in categorizing oral exposure as low, moderate, or high; therefore, the truncated AUC6h derived from pooled plasma samples is suitable for oral exposure screening. The CARRS profiles did not provide reliable half-life estimates; however, compounds with substantial AUC beyond 6 hours can be identified when (C6h/Cmax × 100%) exceeds 80%. Of interest, both the observed data and the simulated data indicated that AUC6h can be estimated using a single time point plasma concentration at 3 hours. The relationship between the maximum biovailability and AUC∞ over a range of clearane values was simulated. A threshold AUC (500 h*ng/mL) at the routine screening dose of 10 mg/kg was established below which a compound can be discarded. Examination of screening results for 5289 compounds evaluated over the last few years in our laboratory indicated that CARRS had a filtering efficiency of 50%, suggesting that this criterion provides a useful decision gate to avoid wasting the drug discovery resources on nonviable candidates.

Keywords: oral exposure, pharmacokinetics, rat, screen

Full Text

The Full Text of this article is available as a PDF (382.6 KB).

References

  • 1.White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol. 2000;40:133–157. doi: 10.1146/annurev.pharmtox.40.1.133. [DOI] [PubMed] [Google Scholar]
  • 2.Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica. 2001;31:557–589. doi: 10.1080/00498250110060978. [DOI] [PubMed] [Google Scholar]
  • 3.Allen MC, Shah TS, Day WW. Rapid determination, of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application. Pharm Res. 1998;15:93–97. doi: 10.1023/A:1011909022226. [DOI] [PubMed] [Google Scholar]
  • 4.Shaffer JE, Adison KK, Halm K, Hedeen K, Berman J. Use of “N-in-one” dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. J Pharm Sci. 1999;88:313–318. doi: 10.1021/js980292q. [DOI] [PubMed] [Google Scholar]
  • 5.Kuo BS, Van Noord T, Feng MR, Wright DS. Sample pooling to expedite bioanalysis and pharmacokinetic research. J Pharm Biomed Anal. 1998;16:837–846. doi: 10.1016/S0731-7085(97)00133-7. [DOI] [PubMed] [Google Scholar]
  • 6.Hop CE, Wang Z, Chen Q, Kei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 1998;87:901–903. doi: 10.1021/js970486q. [DOI] [PubMed] [Google Scholar]
  • 7.Cox KA, Dunn-Meynell K, Korfimacher W, et al. Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discov Today. 1999;4:232–237. doi: 10.1016/S1359-6446(98)01299-9. [DOI] [PubMed] [Google Scholar]
  • 8.Hsieh Y, Bryant MS, Brisson JM, Ng K, Korfimacher WA. Direct cocktail analysis of drug discovery compounds in pooled plasma samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767:353–362. doi: 10.1016/S1570-0232(01)00608-0. [DOI] [PubMed] [Google Scholar]
  • 9.White RE, Manitpisitkul P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos. 2001;29:957–966. [PubMed] [Google Scholar]
  • 10.Korfinacher W, Cox K, Ng K, et al. Cassette-accelerating rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Comm Mass Spec. 2001;15:335–340. doi: 10.1002/rcm.235. [DOI] [PubMed] [Google Scholar]
  • 11.Korfinacher W. Bioanalytical assays in a drug discovery environment. In: Korfimacher W, editor. Using Mass Spectrometry for Drug Metabolism Studies. Boca Raton, FL: CRC Press; 2004. pp. 1–34. [Google Scholar]
  • 12.Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, Stockholm, Sweden. Swed Pharm Press. 2000;345:424–424. [Google Scholar]
  • 13.Boxenbaum H, D’Souza RW. Interspecies pharmacokinetic scaling, biological design and neoteny. Adv Drug Res. 1990;19:139–196. [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES